# A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

> **NCT04827810** · PHASE1 · RECRUITING · sponsor: **Fox Chase Cancer Center** · enrollment: 42 (estimated)

## Conditions studied

- Lymphoma
- Advanced Solid Tumor

## Interventions

- **DRUG:** Gamitrinib

## Key facts

- **NCT ID:** NCT04827810
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-05
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-06-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04827810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04827810, "A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04827810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*